

**Asia Pacific Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)**

Market Report | 2023-02-10 | 146 pages | The Insight Partners

**AVAILABLE LICENSES:**

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

**Report description:**

The Asia Pacific pulmonary arterial hypertension market is expected to grow from US\$ 1,531.47 million in 2022 to US\$ 2,236.62 million by 2028; it is estimated to grow at a CAGR of 6.5% from 2022 to 2028.

Rising Clinical Trials for Drug Development to Treat Pulmonary Arterial Hypertension to Fuel Asia Pacific Pulmonary Arterial Hypertension Market in Coming Years

Growing advancements in understanding the genetic and molecular mechanisms that drive the pathogenesis of the disease are supporting the development of PAH therapies. With the growing knowledge, the treatment strategies will continue to evolve and diversify from the current paradigm focused on vasoconstriction. Clinical trials are exploring the clinical efficacy of novel delivery devices and their utility in the treatment of other forms of pulmonary hypertension and combination therapies. This is likely to be the standard for clinical trials in the coming years. Rising clinical trials for drug development to treat pulmonary arterial hypertension are expected to fuel the Asia Pacific pulmonary arterial hypertension market during the forecast period.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Asia Pacific Pulmonary Arterial Hypertension Market Overview

The Asia Pacific pulmonary arterial hypertension market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest market share in 2021, and India is expected to exhibit significant market growth during the forecast period. In China, a large-scale nationwide pulmonary arterial hypertension (PAH) registry-including over 2,000 patients and detailed data on prescription patterns and treatment-was published in 2022, which reported that congenital heart disease-related PAH (45.2%) was reportedly the most common type of PAH in the country. However, the accessibility of PAH drugs in China remains poor, with only a few cities including the costs of drugs in their medical insurance. Hence, financially unstable patients suffering from PAH do not complete the entire treatment period.

Further, the presence of key players and rising pulmonary arterial hypertension drug development in the country are boosting the market in China. Manufacturers focus on expanding their strategic global presence and specialized expertise with exclusive technological capabilities, leading to better PAH drug availability in China. For instance, Toray and Shenzhen Main Luck Pharmaceuticals are preparing to launch Careload in early 2023. In September 2022, Toray Industries, Inc. announced that it had received approval from the National Medical Products Administration (NMPA) in China for Careload tablets to treat pulmonary arterial hypertension. Similarly, in February 2021, Aerami Therapeutics, Inc. announced the signing of an exclusive license and development agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. to develop and commercialize Aerami's drug-device combination product candidate (AER-901) for the treatment of PAH in mainland China, Hong Kong, Macau, and Taiwan. Furthermore, The World Bank Group reported that the current healthcare expenditure of China grew from 4.94% of the total GDP in 2015 to 5.35% in 2019, which is boosting drug development in the country. Hence, the high prevalence of PAH, a rise in healthcare expenditure, and advancements by key players are expected to propel the growth of the pulmonary arterial hypertension market in China.

## Asia Pacific Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US\$ Billion)

### Asia Pacific Pulmonary Arterial Hypertension Market Segmentation

The Asia Pacific pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.

Based on drugs, the Asia Pacific pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Asia Pacific pulmonary arterial hypertension market.

Based on type, the Asia Pacific pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Asia Pacific pulmonary arterial hypertension market.

Based on route of administration, the Asia Pacific pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Asia Pacific pulmonary arterial hypertension market.

Based on distribution channel, the Asia Pacific pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Asia Pacific pulmonary arterial hypertension market.

Based on country, the Asia Pacific pulmonary arterial hypertension market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2022, China registered the largest share in the Asia Pacific pulmonary arterial hypertension

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

market.

Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Asia Pacific pulmonary arterial hypertension market.

## **Table of Contents:**

### TABLE OF CONTENTS

|   |
|---|
| 1. Introduction   |
| 1.1 Scope of the Study  |
| 1.2 The Insight Partners Research Report Guidance   |
| 1.3 Market Segmentation   |
| 1.3.1 APAC Pulmonary Arterial Hypertension Market - By Drugs  |
| 1.3.2 APAC Pulmonary Arterial Hypertension Market - By Type   |
| 1.3.3 APAC Pulmonary Arterial Hypertension Market - By Route of Administration  |
| 1.3.4 APAC Pulmonary Arterial Hypertension Market - By Distribution Channel   |
| 1.3.5 APAC Pulmonary Arterial Hypertension Market - By Country  |
| 2. APAC Pulmonary Arterial Hypertension Market - Key Takeaways  |
| 3. Research Methodology   |
| 3.1 Coverage  |
| 3.2 Secondary Research  |
| 3.3 Primary Research  |
| 4. APAC Pulmonary Arterial Hypertension Market - Market Landscape   |
| 4.1 Overview  |
| 4.2 APAC PEST Analysis  |
| 4.3 Experts Opinion   |
| 5. APAC Pulmonary Arterial Hypertension Market - Key Market Dynamics  |
| 5.1 Market Drivers  |
| 5.1.1 Growing Incidence of Pulmonary Arterial Hypertension  |
| 5.1.2 Rising Approvals of Pulmonary Arterial Hypertension Drugs   |
| 5.2 Market Restraints   |
| 5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension   |
| 5.3 Market Opportunities  |
| 5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration   |
| 5.4 Future Trend  |
| 5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension   |
| 5.5 Impact analysis   |
| 6. Pulmonary Arterial Hypertension Market - APAC Analysis   |
| 6.1 APAC Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis   |
| 7. APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs  |
| 7.1 Overview  |
| 7.2 APAC Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)   |
| 7.3 Endothelin Receptor Antagonists (ERAs)  |
| 7.3.1 Overview  |
| 7.3.2 Endothelin Receptor Antagonists (ERAs): APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million) |
| 7.4 Prostacyclin and Prostacyclin Analogs   |
| 7.4.1 Overview  |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

7.4.2 Prostacyclin and Prostacyclin Analogs: APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

7.5 SGC Stimulators

7.5.1 Overview

7.5.2 sGC Stimulators: APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

7.6 Pde-5 Dipsticks

7.6.1 Overview

7.6.2 Pde-5 Dipsticks: APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

8. APAC Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type

8.1 Overview

8.2 APAC Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)

8.3 Branded

8.3.1 Overview

8.3.2 Branded: APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

8.4 Generics

8.4.1 Overview

8.4.2 Generics: APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

9. APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration

9.1 Overview

9.2 APAC Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)

9.3 Oral

9.3.1 Overview

9.3.2 Oral: APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

9.4 Intravenous/ Subcutaneous

9.4.1 Overview

9.4.2 Intravenous/ Subcutaneous: APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

9.5 Inhalational

9.5.1 Overview

9.5.2 Inhalational: APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

10. APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel

10.1 Overview

10.2 APAC Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)

10.3 Hospital Pharmacies and Clinics

10.3.1 Overview

10.3.2 Hospital Pharmacies and Clinics: APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

10.4 Online Pharmacies

10.4.1 Overview

10.4.2 Online Pharmacies: APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

10.5 Retail Pharmacies

10.5.1 Overview

10.5.2 Retail Pharmacies: APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

11. APAC Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Country Analysis

11.1 Overview

11.1.1 Asia Pacific: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)

11.1.1.1 China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)

11.1.1.1.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.1.1.1.2 China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.1.1.3 China: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US\$ Million)
- 11.1.1.1.4 China: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US\$ Million)
- 11.1.1.1.5 China Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US\$ Million)
- 11.1.1.1.6 China Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US\$ Million)
- 11.1.1.2 Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.1.2.1 Overview
- 11.1.1.2.2 Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.1.2.3 Japan: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US\$ Million)
- 11.1.1.2.4 Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US\$ Million)
- 11.1.1.2.5 Japan: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US\$ Million)
- 11.1.1.2.6 Japan: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US\$ Million)
- 11.1.1.3 India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.1.3.1 Overview
- 11.1.1.3.2 India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.1.3.3 India: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US\$ Million)
- 11.1.1.3.4 India: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US\$ Million)
- 11.1.1.3.5 India: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US\$ Million)
- 11.1.1.3.6 India: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US\$ Million)
- 11.1.1.4 South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.1.4.1 Overview
- 11.1.1.4.2 South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.1.4.3 South Korea: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US\$ Million)
- 11.1.1.4.4 South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US\$ Million)
- 11.1.1.4.5 South Korea: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US\$ Million)
- 11.1.1.4.6 South Korea: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US\$ Million)
- 11.1.1.5 Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.1.5.1 Overview
- 11.1.1.5.2 Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.1.5.3 Australia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US\$ Million)
- 11.1.1.5.4 Australia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US\$ Million)
- 11.1.1.5.5 Australia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US\$ Million)
- 11.1.1.5.6 Australia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US\$ Million)
- 11.1.1.6 Rest of APAC: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.1.6.1 Overview
- 11.1.1.6.2 Rest of APAC: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.1.6.3 Rest of APAC: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US\$ Million)
- 11.1.1.6.4 Rest of APAC: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US\$ Million)
- 11.1.1.6.5 Rest of APAC: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US\$ Million)
- 11.1.1.6.6 Rest of APAC: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US\$ Million)
- 12. APAC Pulmonary Arterial Hypertension Market - Industry Landscape
- 12.1 Overview
- 12.2 Organic Developments
- 12.2.1 Overview
- 12.3 Inorganic Developments
- 12.3.1 Overview
- 13. Company Profiles

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.1 Johnson & Johnson
  - 13.1.1 Key Facts
  - 13.1.2 Business Description
  - 13.1.3 Products and Services
  - 13.1.4 Financial Overview
  - 13.1.5 SWOT Analysis
  - 13.1.6 Key Developments
- 13.2 Gilead Sciences Inc
  - 13.2.1 Key Facts
  - 13.2.2 Business Description
  - 13.2.3 Products and Services
  - 13.2.4 Financial Overview
  - 13.2.5 SWOT Analysis
  - 13.2.6 Key Developments
- 13.3 Bayer AG
  - 13.3.1 Key Facts
  - 13.3.2 Business Description
  - 13.3.3 Products and Services
  - 13.3.4 Financial Overview
  - 13.3.5 SWOT Analysis
  - 13.3.6 Key Developments
- 13.4 Novartis AG
  - 13.4.1 Key Facts
  - 13.4.2 Business Description
  - 13.4.3 Products and Services
  - 13.4.4 Financial Overview
  - 13.4.5 SWOT Analysis
  - 13.4.6 Key Developments
- 13.5 GSK Plc
  - 13.5.1 Key Facts
  - 13.5.2 Business Description
  - 13.5.3 Products and Services
  - 13.5.4 Financial Overview
  - 13.5.5 SWOT Analysis
  - 13.5.6 Key Developments
- 13.6 Teva Pharmaceutical Industries Ltd
  - 13.6.1 Key Facts
  - 13.6.2 Business Description
  - 13.6.3 Products and Services
  - 13.6.4 Financial Overview
  - 13.6.5 SWOT Analysis
  - 13.6.6 Key Developments
- 13.7 Lupin Ltd
  - 13.7.1 Key Facts
  - 13.7.2 Business Description
  - 13.7.3 Products and Services
  - 13.7.4 Financial Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Pfizer Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms

**Asia Pacific Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)**

Market Report | 2023-02-10 | 146 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

| Select license | License           | Price     |
|----------------|-------------------|-----------|
|                | Single User Price | \$3000.00 |
|                | Site Price        | \$4000.00 |
|                | Enterprise Price  | \$5000.00 |
|                |                   | VAT       |
|                |                   | Total     |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|             |                      |            |                      |
|-------------|----------------------|------------|----------------------|
| Email*      | <input type="text"/> | Phone*     | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title*  | <input type="text"/> |            |                      |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

|               |                      |                               |   |
|---------------|----------------------|-------------------------------|---|
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/>                    |
| Address*      | <input type="text"/> | City*                         | <input type="text"/>                    |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/>                    |
|               |                      | Date                          | <input type="text" value="2025-05-10"/> |
|               |                      | Signature                     | <input type="text"/>                    |